Latest News
Circassia Acquires North American and Japanese rights to Dopexamine
08 October 2008
Circassia Initiates Further Phase II Clinical Study Of ToleroMune® Anti-Allergy Technology
02 October 2008
Circassia Achieves Successful Phase II Clinical Results With ToleroMune® Anti-Allergy Technology
10 September 2008
Circassia Announces the Appointment of Guy Layton as Director of Alloimmune Projects
02 June 2008
Circassia Announces the Appointment of Pascal Hickey as Vice President, Critical Care
21 April 2008
Did you know?
The average bed could be home to up to 1.5 million house dust mites